Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ib pediatric study of crizotinib-based therapy in ALK/MET/ROS1-positive malignancies
NL-OMON24969Phase 1Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of crizotinib, vinblastine and temsirolimus in anaplastic large cell lymphoma (ALCL), neuroblastoma, rhabdomyosarcoma (RMS) and 3 more, sponsored by Erasmus MC. Primary endpoints: Dose-limiting toxicities and Overall response rate. Started Jun 2016; status: recruiting.
02
Drugs
crizotinibvinblastinetemsirolimus
03
Conditions
anaplastic large cell lymphoma (ALCL)neuroblastomarhabdomyosarcoma (RMS)solid tumorNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON24969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON24969.